Clinical Trials · NCT00913055

Open Label Study of Octreotide Implant in Patients With Acromegaly

CompletedPhase 2Octreotide (Approved)
Phase
Phase 2
Recruitment status
Completed
Sponsor
Endo USA Inc., a Keenova Therapeutics Company
Enrollment
34
Start date
Feb 2007
Locations
See registry
Primary endpoint
Study in Acromegaly
View Octreotide compound reference